BUY-SIDE

Analyst

Visible Alpha Insights provides an innovative, integrated experience and instant access to full working sell-side models, granular consensus estimates and industry-level analysis to optimize your workflow, improve efficiency and boost your confidence in recommending investment ideas.

DIVE DEEPER

Hone in on the fundamental drivers of companies important to you

INCREASE EFFICIENCY

Instantly discover investment controversies and compare line items at an industry level

CUSTOMIZE YOUR EXPERIENCE

Integrate broker and consensus data directly into your own models

Optimize Your Workflow:

Normalized Data: Compare company line items across analysts and side-by-side with consensus
Standardized Data: Build comprehensive comp tables with industry-specific operating metrics
Pre- and Post-Earnings Analysis: Create custom automated earnings previews and leverage surprise and revisions analysis tools for past company performance
Real-Time Access: Receive model revisions in real time and access the latest consensus estimates
Integrated Sell-Side Content: Leverage our powerful research viewer to interact with model data while reading research reports
Excel Add-In: Export the Street’s most up-to-date forecasts directly into your models

Products We Offer:

Insights

“Visible Alpha saves me hours each week by updating consensus metrics for companies in my coverage”

Analyst, $750M Long-Short Hedge Fund

“I have built in Visible Alpha ‘consensus’ sheets into all my models.”

Analyst, $1B Credit Hedge Fund

“You have interesting data that I can’t find anywhere else.”

Analyst, $8-12B Multi-Strategy Fund

“I used to spend 5 hours doing [research and analysis], now I spend 2 minutes”

Analyst, $1.5B Directional Hedge Fund

Excel Add-In for Insights

Leverage the power of Visible Alpha Insights directly in Excel
Incorporate the latest analyst and consensus forecasts directly into your own models. Easily identify bullish or bearish trends by seeing how estimates have changed over time, and see how revisions for key drivers have changed compared to your own estimates.

Learn More

“Your plug-in is a game-changer.”
— Analyst, $20-25B Activist Long/Short Hedge Fund

Request A Demo

13,500,000+

Total Analyst Line Items Available

as of Jan 2020

100+

Contributing Brokers

4,800+

Company Coverage

157

Average Consensus Lines Per Company

70,000+

Model Revisions Processed Last Quarter

Services

We are here to empower you to achieve your goals

Increasing Coverage
We’re constantly increasing coverage across the globe, but if a broker or company you want is not on the platform, we’ll work with you to onboard them or initiate coverage.

Continuous Enhancements
With a SaaS model, you will always have the latest version of our product, as we work on an endless cycle to solicit and incorporate client feedback into new features and capabilities.

Effortless Onboarding
We will guide you through discovering the available features, functions and capabilities, and work with you to integrate the product to best enhance your current workflow.

Learn More

Major U.S. Airlines Are Not Expected To Recover From COVID Until 2022 At The Earliest

Wall Street analysts believe the four largest U.S. airlines – Delta (DAL), United (UAL), American (AAL) and Southwest (LUV) – will lose 50-60% of their revenue from COVID-19 as they struggle with unfathomable demand shock and restricted travel conditions. Many analysts also point out the risk of a structural change…

Snapchat, Facebook Expected To Weather Covid-19 Storm Better Than Peers

The Covid-19 pandemic is shifting a larger portion of consumer budgets online and shaking up the digital advertising industry. Analysts believe Snapchat and Facebook are best positioned to weather the storm with advantageous Direct-Response (DR) ad products that offer a direct transactional link that can generate higher returns on ad…

Gilead Analysts Begin Forecasting Remdesivir Sales for Covid-19 Treatment

The U.S. Food and Drug Administration (FDA) recently approved Gilead’s antiviral Remdesivir for emergency use authorization (EUA) as a treatment for COVID-19 in severe stages. Gilead is donating their current supply of about 1.5M individual doses, equating to more than 140K treatment courses (assuming a 10-day treatment course), which will…

Analyst

DIVE DEEPER

INCREASE EFFICIENCY

CUSTOMIZE YOUR EXPERIENCE

Optimize Your Workflow:

Products We Offer:

Excel Add-In for Insights

“Your plug-in is a game-changer.”
— Analyst, $20-25B Activist Long/Short Hedge Fund

Request A Demo

100+

4,800+

157

70,000+

Services

Major U.S. Airlines Are Not Expected To Recover From COVID Until 2022 At The Earliest

Snapchat, Facebook Expected To Weather Covid-19 Storm Better Than Peers

Gilead Analysts Begin Forecasting Remdesivir Sales for Covid-19 Treatment

Request A Demo

Get Started

Client Access

Call Us

Analyst

Optimize Your Workflow:

Products We Offer:

Excel Add-In for Insights

“Your plug-in is a game-changer.”— Analyst, $20-25B Activist Long/Short Hedge Fund

Request A Demo

100+

4,800+

157

70,000+

Services

Request A Demo

Get Started

Client Access

Call Us

Join Our Newsletter

“Your plug-in is a game-changer.”
— Analyst, $20-25B Activist Long/Short Hedge Fund